Related references
Note: Only part of the references are listed.A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma
Franck Morschhauser et al.
BLOOD (2021)
Cytotoxic CD8+T cells in cancer and cancer immunotherapy
Hans Raskov et al.
BRITISH JOURNAL OF CANCER (2021)
Regulatory B cells in cancer
Daniel Michaud et al.
IMMUNOLOGICAL REVIEWS (2021)
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
Marc Armengol et al.
CANCERS (2021)
miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors
Florian Huemer et al.
PHARMACEUTICALS (2021)
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management
Sandra Susanibar-Adaniya et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL
Lorena Fontan et al.
BLOOD (2021)
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures
Nikita Kotlov et al.
CANCER DISCOVERY (2021)
Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial
Martin Hutchings et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Zheng Tian et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Immunosuppressive Mechanisms of Regulatory B Cells
Diego Catalan et al.
FRONTIERS IN IMMUNOLOGY (2021)
Treating lymphoma is now a bit EZ-er
Ryan D. Morin et al.
BLOOD ADVANCES (2021)
PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges
Eileen McGowan et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Regulatory B cells in infection, inflammation, and autoimmunity
Subhajit Dasgupta et al.
CELLULAR IMMUNOLOGY (2020)
Regulation of the germinal center and humoral immunity by interleukin-21
Stuart G. Tangye et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Enli Liu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Follicular Regulatory T Cells Can Access the Germinal Center Independently of CXCR5
Ine Vanderleyden et al.
CELL REPORTS (2020)
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
George W. Wright et al.
CANCER CELL (2020)
Immunotherapy in Hodgkin and non-Hodgkin lymphoma: Innate, adaptive and targeted immunological strategies
Aung M. Tun et al.
CANCER TREATMENT REVIEWS (2020)
PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas
Wei Xie et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2020)
Engineered IL-21 Cytokine Muteins Fused to Anti-PD-1 Antibodies Can Improve CD8+T Cell Function and Anti-tumor Immunity
Shanling Shen et al.
FRONTIERS IN IMMUNOLOGY (2020)
The Tumor Microenvironment of DLBCL in the Computational Era
Giuseppina Opinto et al.
FRONTIERS IN ONCOLOGY (2020)
FROM THE ANALYST'S COUCH Cancer cell therapies: the clinical trial landscape
Jia Xin Yu et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Pembrolizumab in relapsed or refractory Richter syndrome
Philippe Armand et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
T follicular helper cell-mediated IL-21 production suppresses FOXP3 expression of T follicular regulatory-like cells in diffuse large B cell lymphoma patients
Xiaomei Ma et al.
HUMAN IMMUNOLOGY (2020)
Control of foreign Ag-specific Ab responses by Treg and Tfr
James B. Wing et al.
IMMUNOLOGICAL REVIEWS (2020)
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
Nagesh Kalakonda et al.
Lancet Haematology (2020)
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies
Stephen M. Ansell et al.
BLOOD ADVANCES (2020)
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
Gilles Salles et al.
LANCET ONCOLOGY (2020)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Jeremy S. Abramson et al.
LANCET (2020)
P53-regulated miR-320a targets PDL1 and is downregulated in malignant mesothelioma
Caterina Costa et al.
CELL DEATH & DISEASE (2020)
The multifaceted functions of follicular regulatory T cells
Peter T. Sage et al.
CURRENT OPINION IN IMMUNOLOGY (2020)
New agents and regimens for diffuse large B cell lymphoma
Liang Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Genetic and epigenetic determinants of diffuse large B-cell lymphoma
Tanner J. Bakhshi et al.
BLOOD CANCER JOURNAL (2020)
Regulation of PD-L1 Expression by NF-κB in Cancer
Fabrizio Antonangeli et al.
FRONTIERS IN IMMUNOLOGY (2020)
Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome
Helene Auge et al.
FRONTIERS IN IMMUNOLOGY (2020)
PD-1 is highly expressed by neoplastic B-cells in Richter transformation
Amir Behdad et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Use of PD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre
Kerry A. Rogers et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies
Andres Forero-Torres et al.
BLOOD (2019)
PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype
James Godfrey et al.
BLOOD (2019)
Molecular pathogenesis of germinal center-derived B cell lymphomas
Laura Pasqualucci
IMMUNOLOGICAL REVIEWS (2019)
Germinal center-derived lymphomas: The darkest side of humoral immunity
Coraline Mlynarczyk et al.
IMMUNOLOGICAL REVIEWS (2019)
Understanding Immune Evasion and Therapeutic Targeting Associated with PD-1/PD-L1 Pathway in Diffuse Large B-cell Lymphoma
Moo-Kon Song et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy
Siyu Deng et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Emerging epigenetic-modulating therapies in lymphoma
David Sermer et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas
Marien Pascual et al.
BLOOD (2019)
PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1/PD-L1-dependent pathway
Xufu Wang et al.
MOLECULAR IMMUNOLOGY (2019)
Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer
Shabnum Patel et al.
FRONTIERS IN ONCOLOGY (2019)
Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss
Ali Bukhari et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell-like DLBCL
Andre Goy et al.
BLOOD (2019)
ROBUST: First report of phase III randomized study of lenalidomide/R-CHOP (R2 -CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma
U. Vitolo et al.
HEMATOLOGICAL ONCOLOGY (2019)
ADDITION OF LENALIDOMIDE TO R-CHOP (R2CHOP) IMPROVES OUTCOMES IN NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): FIRST REPORT OF ECOG-ACRIN1412 A RANDOMIZED PHASE 2 US INTERGROUP STUDY OF R2CHOP VS R-CHOP
G.S. Nowakowski et al.
HEMATOLOGICAL ONCOLOGY (2019)
CLINICAL ACTIVITY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY (AB) IN PATIENTS (PTS) WITH (W/) RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
M.S. Topp et al.
HEMATOLOGICAL ONCOLOGY (2019)
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
Weiping Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
Cristina Segovia et al.
NATURE MEDICINE (2019)
Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas
Xiaoguang Wang et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
Xiangfeng Shen et al.
FRONTIERS IN IMMUNOLOGY (2019)
T follicular regulatory cells suppress Tfh-mediated B cell help and synergistically increase IL-10-producing B cells in breast carcinoma
Hongsheng Song et al.
IMMUNOLOGIC RESEARCH (2019)
IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression
Alexander Thiem et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation
Patrizia Murer et al.
NEW BIOTECHNOLOGY (2019)
Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma
Yucai Wang et al.
BLOOD CANCER JOURNAL (2019)
Regulatory functions of B cells and regulatory plasma cells
Simon Fillatreau
BIOMEDICAL JOURNAL (2019)
Combination of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor T Cells for Relapsed and Refractory Diffuse Larger B Cell Lymphoma: An Open-Label, Single-Arm, Phase I/II Trial
Wei Sang et al.
BLOOD (2019)
Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results
Jason R. Westin et al.
BLOOD (2019)
CXCR5+PD-1+ follicular helper CD8 T cells control B cell tolerance
Yuhong Chen et al.
NATURE COMMUNICATIONS (2019)
EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma
Gang Xiao et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study
Kirit M. Ardeshna et al.
BLOOD (2019)
Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma
Alex F. Herrera et al.
BLOOD (2019)
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
Stephen M. Ansell et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
BCL6-Mediated Silencing of PD-1 Ligands in Germinal Center B Cells Maintains Follicular T Cell Population
Cheng Peng et al.
JOURNAL OF IMMUNOLOGY (2019)
Translation control of the immune checkpoint in cancer and its therapeutic targeting
Yichen Xu et al.
NATURE MEDICINE (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
Anas Younes et al.
LANCET HAEMATOLOGY (2019)
Hiv and Lymphoma: from Epidemiology to Clinical Management
Alessandro Re et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2019)
Immunochemotherapy for Richter syndrome: current insights
Bartosz Pula et al.
IMMUNOTARGETS AND THERAPY (2019)
Chronic hepatitis B virus infection is associated with a poorer prognosis in diffuse large B-cell lymphoma: a meta-analysis and systemic review
Xingyu Rong et al.
JOURNAL OF CANCER (2019)
CD274 (PD-L1)/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma
Anna Kwiecinska et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models
Katherine E. Lewis et al.
ONCOIMMUNOLOGY (2018)
PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT) A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness
Rong He et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Overexpressed miR-195 attenuated immune escape of diffuse large B-cell lymphoma by targeting PD-L1
Bai He et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma
Tycel J. Phillips et al.
BLOOD (2018)
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Marina Bacac et al.
CLINICAL CANCER RESEARCH (2018)
The prevalence and function of CD4+ CXCR5+ Foxp3+ follicular regulatory T cells in diffuse large B cell lymphoma
Zhanshan Cha et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
CD8 Follicular T Cells Promote B Cell Antibody Class Switch in Autoimmune Disease
Kristen M. Valentine et al.
JOURNAL OF IMMUNOLOGY (2018)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy et al.
NATURE MEDICINE (2018)
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
R. Schmitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cooperative STAT/NF-kappa B signaling regulates lymphoma metabolic reprogramming and aberrant GOT2 expression
Maren Feist et al.
NATURE COMMUNICATIONS (2018)
Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL (vol 8, 744, 2018)
Kavita Bhalla et al.
SCIENTIFIC REPORTS (2018)
B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma
Li Li et al.
BLOOD (2018)
PD-1 Controls Follicular T Helper Cell Positioning and Function
Jingwen Shi et al.
IMMUNITY (2018)
Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth
Lorena Fontan et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Martin J. S. Dyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma
Jun Zhang et al.
FRONTIERS IN ONCOLOGY (2018)
Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue
S. Ciavarella et al.
ANNALS OF ONCOLOGY (2018)
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Miguel F. Sanmamed et al.
CELL (2018)
Natural regulatory plasma cells
Simon Fillatreau
CURRENT OPINION IN IMMUNOLOGY (2018)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A Subset of CXCR5+ CD8+ T Cells in the Germinal Centers From Human Tonsils and Lymph Nodes Help B Cells Produce Immunoglobulins
Juan Shen et al.
FRONTIERS IN IMMUNOLOGY (2018)
End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma
Caron A. Jacobson et al.
BLOOD (2018)
Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies
Nasheed Hossain et al.
BLOOD (2018)
CXCR5 and ICOS expression identifies a CD8 T-cell subset with TFH features in Hodgkin lymphomas
Kieu-Suong Le et al.
BLOOD ADVANCES (2018)
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Zijun Y. Xu-Monette et al.
BLOOD (2018)
Interleukin 21-its potential role in the therapy of B-cell lymphomas
Shruti Bhatt et al.
LEUKEMIA & LYMPHOMA (2017)
Interleukin 10 enhanced CD8+ T cell activity and reduced CD8+ T cell apoptosis in patients with diffuse large B cell lymphoma
Huiying Qiu et al.
EXPERIMENTAL CELL RESEARCH (2017)
Circulating CXCR5+CD4+T cells assist in the survival and growth of primary diffuse large B cell lymphoma cells through interleukin 10 pathway
Zhanshan Cha et al.
EXPERIMENTAL CELL RESEARCH (2017)
Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics
Maria A. Smolle et al.
FEBS JOURNAL (2017)
Human regulatory B cells control the TFH cell response
Achouak Achour et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Trp53 fl/fl Pten fl/fl mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging
Marisa R. Buchakjian et al.
PLOS ONE (2017)
Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies
Edurne San Jose-Eneriz et al.
NATURE COMMUNICATIONS (2017)
BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1
Simon J. Hogg et al.
CELL REPORTS (2017)
The Other Function: Class II-Restricted Antigen Presentation by B Cells
Lital N. Adler et al.
FRONTIERS IN IMMUNOLOGY (2017)
Interleukin-10 from CD4+ follicular regulatory T cells promotes the germinal center response
Brian J. Laidlaw et al.
SCIENCE IMMUNOLOGY (2017)
Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma
Reid W. Merryman et al.
BLOOD ADVANCES (2017)
Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors
Si Li et al.
CLINICAL CANCER RESEARCH (2017)
The transcription factor Runx3 guards cytotoxic CD8+ effector T cells against deviation towards follicular helper T cell lineage
Qiang Shan et al.
NATURE IMMUNOLOGY (2017)
B cell regulation in cancer and anti-Xtumor immunity
Anushruti Sarvaria et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2017)
Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
Wei Ding et al.
BLOOD (2017)
Infiltration of effector regulatory T cells predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified
Shoko Nakayama et al.
BLOOD ADVANCES (2017)
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer
Kristin J. Lastwika et al.
CANCER RESEARCH (2016)
Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas
Dohee Kwon et al.
HISTOPATHOLOGY (2016)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Follicular Helper T Cells
Carola G. Vinuesa et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)
Tumor microenvironment (TME)-driven immune suppression in B cell malignancy
Nicole S. Nicholas et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2016)
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma
A. Viardot et al.
BLOOD (2016)
Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas
Konstantinos Georgiou et al.
BLOOD (2016)
Potential role for R191 potent and selective IRAK4 kinase inhibitor, in treatment of hematologic malignancies
Vadim V. Markovtsov et al.
CANCER RESEARCH (2016)
Combination therapy of immune checkpoint and nuclear exporter inhibitors in a renal cell carcinoma mouse model
Josephine Trott et al.
CANCER RESEARCH (2016)
Follicular regulatory T cells repress cytokine production by follicular helper T cells and optimize IgG responses in mice
Hao Wu et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2016)
Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas
Thomas Menter et al.
HUMAN PATHOLOGY (2016)
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
Alexander M. Lesokhin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Keisuke Kataoka et al.
NATURE (2016)
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Vassiliki A. Boussiotis
NEW ENGLAND JOURNAL OF MEDICINE (2016)
MYC regulates the antitumor immune response through CD47 and PD-L1
Stephanie C. Casey et al.
SCIENCE (2016)
PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression
Xiao Xiao et al.
CANCER DISCOVERY (2016)
Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
Eloah Rabello Suarez et al.
ONCOTARGET (2016)
PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications
Wei Xing et al.
ONCOTARGET (2016)
Follicular Regulatory CD8 T Cells Impair the Germinal Center Response in SIV and Ex Vivo HIV Infection
Brodie Miles et al.
PLOS PATHOGENS (2016)
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
Andreas Lundqvist et al.
Journal for ImmunoTherapy of Cancer (2016)
Nivolumab Combined with Ibrutinib for CLL and Richter Transformation: A Phase II Trial
Nitin Jain et al.
BLOOD (2016)
High Levels of Regulatory T Cells in Blood Are a Poor Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma
Chen Chang et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2015)
Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma
Junichi Kiyasu et al.
BLOOD (2015)
The role of IL-21 in immunity and cancer
Matthew R. Davis et al.
CANCER LETTERS (2015)
Tumor suppressor miR-34a targets PD-L1 and functions as a potential immunotherapeutic target in acute myeloid leukemia
Xi Wang et al.
CELLULAR SIGNALLING (2015)
Regulatory B Cells: Origin, Phenotype, and Function
Elizabeth C. Rosser et al.
IMMUNITY (2015)
Signals controlling the development and activity of regulatory B-lineage cells
Yoshihiro Baba et al.
INTERNATIONAL IMMUNOLOGY (2015)
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma
John G. Gribben et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy
Priscilla N. Kelly et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
IL10 receptor is a novel therapeutic target in DLBCLs
W. Beguelin et al.
LEUKEMIA (2015)
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wyndham H. Wilson et al.
NATURE MEDICINE (2015)
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma
Patcharee Ritprajak et al.
ORAL ONCOLOGY (2015)
Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK
Idit Sagiv-Barfi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Dissecting the signaling pathways that mediate cancer in PTEN and LKB1 double-knockout mice
Jiezhong Chen et al.
SCIENCE SIGNALING (2015)
T follicular regulatory cells in the regulation of B cell responses
Peter T. Sage et al.
TRENDS IN IMMUNOLOGY (2015)
PD-L1(hi) B cells are critical regulators of humoral immunity
Adnan R. Khan et al.
NATURE COMMUNICATIONS (2015)
Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age
Ting-Xun Lu et al.
SCIENTIFIC REPORTS (2015)
Dissecting the signaling pathways that mediate cancer in PTEN and LKB1 double-knockout mice
Jiezhong Chen et al.
SCIENCE SIGNALING (2015)
IL-21: A Pleiotropic Cytokine with Potential Applications in Oncology
Michela Croce et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2015)
Antibody-independent functions of B cells: a focus on cytokines
Ping Shen et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Germinal centres and B cell lymphomagenesis
Katia Basso et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Dynamics of B cells in germinal centres
Nilushi S. De Silva et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD
Ahmad Khoder et al.
BLOOD (2014)
A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells
Ivraym B. Barsoum et al.
CANCER RESEARCH (2014)
Interleukin-10-Producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation
Masanori Matsumoto et al.
IMMUNITY (2014)
A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors
Sven de Vos et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
B Cell Antigen Presentation in the Initiation of Follicular Helper T Cell and Germinal Center Differentiation
Lisa G. Barnett et al.
JOURNAL OF IMMUNOLOGY (2014)
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
D. Rossille et al.
LEUKEMIA (2014)
Interleukin-21: a double-edged sword with therapeutic potential
Rosanne Spolski et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells
Lesley A. Mathews Griner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Alterations of circulating follicular helper T cells and interleukin 21 in diffuse large B-cell lymphoma
Zhanshan Cha et al.
TUMOR BIOLOGY (2014)
Effect of interleukin 21 and its receptor on CD8+ T cells in the pathogenesis of diffuse large B-cell lymphoma
Zhanshan Cha et al.
ONCOLOGY LETTERS (2014)
The tumour microenvironment in B cell lymphomas
David W. Scott et al.
NATURE REVIEWS CANCER (2014)
A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency
Benedicte Neven et al.
BLOOD (2013)
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Benjamin J. Chen et al.
CLINICAL CANCER RESEARCH (2013)
PD-1 is a novel regulator of human B-cell activation
Marie-Laure Thibult et al.
INTERNATIONAL IMMUNOLOGY (2013)
PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis
Bernd H. Zinselmeyer et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Follicular T-helper cell recruitment governed by bystander B cells and ICOS-driven motility
Heping Xu et al.
NATURE (2013)
The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood
Peter T. Sage et al.
NATURE IMMUNOLOGY (2013)
PD-1 as a potential target in cancer therapy
David F. McDermott et al.
CANCER MEDICINE (2013)
Immune Regulatory Function of B Cells
Claudia Mauri et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
Zijun Y. Xu-Monette et al.
BLOOD (2012)
Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas
Gabriel D. Victora et al.
BLOOD (2012)
Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer
Alan G. Ramsay et al.
BLOOD (2012)
Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma
Stefano Monti et al.
CANCER CELL (2012)
IL-10 Directly Activates and Expands Tumor-Resident CD8+ T Cells without De Novo Infiltration from Secondary Lymphoid Organs
Jan Emmerich et al.
CANCER RESEARCH (2012)
STAT5 Protein Negatively Regulates T Follicular Helper (Tfh) Cell Generation and Function
Roza I. Nurieva et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
STAT5 is a potent negative regulator of TFH cell differentiation
Robert J. Johnston et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
Tadashi Yokosuka et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
Michael T. McCabe et al.
NATURE (2012)
The Inhibitory Receptor PD-1 Regulates IgA Selection and Bacterial Composition in the Gut
Shimpei Kawamoto et al.
SCIENCE (2012)
IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
John B. Mumm et al.
CANCER CELL (2011)
Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
David J. Andorsky et al.
CLINICAL CANCER RESEARCH (2011)
Both CD4+FoxP3+and CD4+FoxP3-T cells from patients with B-cell malignancy express cytolytic markers and kill autologous leukaemic B cells in vitro
Camilla A. Lindqvist et al.
IMMUNOLOGY (2011)
The Four types of Tregs in malignant lymphomas
Jing Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
Blockade of B7-H1 (Programmed Death Ligand 1) Enhances Humoral Immunity by Positively Regulating the Generation of T Follicular Helper Cells
Emily Hams et al.
JOURNAL OF IMMUNOLOGY (2011)
Mice Lacking Endogenous IL-10-Producing Regulatory B Cells Develop Exacerbated Disease and Present with an Increased Frequency of Th1/Th17 but a Decrease in Regulatory T Cells
Natalie A. Carter et al.
JOURNAL OF IMMUNOLOGY (2011)
Regulation of the Germinal Center Reaction by Foxp3+ Follicular Regulatory T Cells
Ivonne Wollenberg et al.
JOURNAL OF IMMUNOLOGY (2011)
Analysis of the coding genome of diffuse large B-cell lymphoma
Laura Pasqualucci et al.
NATURE GENETICS (2011)
Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions
Yeonseok Chung et al.
NATURE MEDICINE (2011)
Foxp3+ follicular regulatory T cells control the germinal center response
Michelle A. Linterman et al.
NATURE MEDICINE (2011)
Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells
Katia Basso et al.
BLOOD (2010)
Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas
Kristopher A. Sarosiek et al.
BLOOD (2010)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
B7-H1 expression on non-B and non-T cells promotes distinct effects on T- and B-cell responses in autoimmune arthritis
Keith M. Hamel et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
CD19+CD24hiCD38hi B Cells Exhibit Regulatory Capacity in Healthy Individuals but Are Functionally Impaired in Systemic Lupus Erythematosus Patients
Paul A. Blair et al.
IMMUNITY (2010)
IL-21 regulates germinal center B cell differentiation and proliferation through a B cell-intrinsic mechanism
Dimitra Zotos et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Cutting Edge: Programmed Death-1 Defines CD8+ CD122+ T Cells as Regulatory versus Memory T Cells
Hehua Dai et al.
JOURNAL OF IMMUNOLOGY (2010)
Inhibition of follicular T-helper cells by CD8+ regulatory T cells is essential for self tolerance
Hye-Jung Kim et al.
NATURE (2010)
PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells
Kim L. Good-Jacobson et al.
NATURE IMMUNOLOGY (2010)
Interleukin-21 effectively induces apoptosis in mantle cell lymphoma through a STAT1-dependent mechanism
P. Gelebart et al.
LEUKEMIA (2009)
Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma
Ana I. Saez et al.
LEUKEMIA & LYMPHOMA (2009)
Cytokine-secreting follicular T cells shape the antibody repertoire
R. Lee Reinhardt et al.
NATURE IMMUNOLOGY (2009)
Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma
Lloyd T. Lam et al.
BLOOD (2008)
Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma
Alexandar Tzankov et al.
HAEMATOLOGICA (2008)
Prognostic impact of tumor infiltrating FOXP3 positive regulatory T cells in diffuse large B-cell lymphoma at diagnosis
Na-Ri Lee et al.
LEUKEMIA & LYMPHOMA (2008)
Stromal Gene Signatures in Large-B-Cell Lymphomas
G. Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Michal Marzec et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas
B. Belinda Ding et al.
BLOOD (2008)
Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1High germinal center-associated subpopulation
Nicole M. Haynes et al.
JOURNAL OF IMMUNOLOGY (2007)
The number of tumour-infiltrating TIA-1+ cytotoxic T cells but not FOXP3+ regulatory T cells predicts outcome in diffuse large B-cell lymphoma
Sverker Hasselblom et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
The germinal center response is impaired in the absence of T cell-expressed CXCR5
Carrie N. Arnold et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma
Joaquim Carreras et al.
BLOOD (2006)
Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells
D de Totero et al.
BLOOD (2006)
The role of ICOS in the CXCR5+ follicular B helper T cell maintenance in vivo
H Akiba et al.
JOURNAL OF IMMUNOLOGY (2005)
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response
S Monti et al.
BLOOD (2005)
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function
R Zeng et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity:: Comparative evaluation of IL-2, IL-15, and IL-21
A Moroz et al.
JOURNAL OF IMMUNOLOGY (2004)
Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest, or bim-dependent apoptosis
HL Jin et al.
JOURNAL OF IMMUNOLOGY (2004)
A critical role for IL-21 in regulating immunoglobulin production
K Ozaki et al.
SCIENCE (2002)
Expression of programmed death 1 ligands by murine T cells and APC
T Yamazaki et al.
JOURNAL OF IMMUNOLOGY (2002)
Microanatomical localization of PD-1 in human tonsils
Y Iwaia et al.
IMMUNOLOGY LETTERS (2002)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
A Rosenwald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
CD8 T cells are required for the formation of ectopic germinal centers in rheumatoid synovitis
YM Kang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine
T Okazaki et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice
J Tian et al.
JOURNAL OF IMMUNOLOGY (2001)
Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function
J Parrish-Novak et al.
NATURE (2000)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
Share Paper
